Back to Atlas
BSemi-durableStandard research/education caution
CMP-0241
Experimental
Tabernanthalog
Nootropic / Psychoplastogen
Structural neuroplasticity, anti-addictive and antidepressant-like effects in models
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- Non-hallucinogenic ibogaine analog; serotonergic neuroplasticity signaling
- Primary market use
- Neuropsychiatry / addiction
Pharmacology
- Molecular weight (Da)
- ~392
- Oral bioavailability
- Unknown
- Half-life
- ~2–12 h small-molecule class estimate
- Route tags
- Route-dependent / verify
- Evidence level
- Preclinical
- Clinical status
- Experimental
- Value-for-money score
- 4 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Durable functional adaptation candidate due to psychoplastogenic mechanism